Chasing Pfizer, GSK's 5-in-1 meningococcal vaccine delivers phase 3 trial win

Nearly three years after dosing the first patient in a phase 3 trial, GSK has now reported positive results from the trial of its much-anticipated combination meningitis vaccine.

The shot, a combination of GSK's approved vaccines Bexsero and Menveo, targets meningitis and blood poisoning caused by the A, B, C, W, and Y groups of meningococcal bacteria.